ACRV — structural market context
Acrivon Therapeutics, Inc. Com
Structural market context from public regulatory and market data, shown with its as-of dates. Descriptive only: nothing on this page is a recommendation, a prediction, or advice to buy or sell any security.
ACRV short interest & days to cover
FINRA consolidated short interest, reported twice a month and published ~2 weeks after each settlement date. % of float uses reported free float. · as of 2026-07-31 (22d ago)
ACRV fails-to-deliver (FTD)
| Settlement date | Failed shares | Price |
|---|
| 2026-07-27 · 26d | 4K | $1.6 |
| 2026-07-10 · 43d | 2 | $2.05 |
| 2026-07-09 · 44d | 4K | $2.04 |
SEC fails-to-deliver files, published twice a month with ~6 weeks of delay.
ACRV insider buying and selling (Form 4)
Last 12 months, open-market only: 0 purchases · 6 sales
| Insider | Type | Shares | Value | Filed |
|---|
| Peterson Katharine · officer: Chief Accounting Officer | Sell (S) | 101 | $203 | 2026-08-20 |
| Miller Mary · officer: Chief Legal Officer | Sell (S) | 185 | $372 | 2026-08-20 |
| Gamelin Erick · officer: Chief Development Officer | Sell (S) | 400 | $804 | 2026-08-20 |
| Devroe Eric · officer: Chief Operating Officer | Sell (S) | 604 | $1K | 2026-08-20 |
| Blume-Jensen Peter · director, officer: President and CEO | Sell (S) | 1K | $2K | 2026-08-20 |
SEC Form 4 filings, open-market purchases and sales only (codes P and S); grants and option exercises excluded. Attributed public records.
Frequently asked questions
What is ACRV's short interest?
As of the FINRA settlement date 2026-07-31, ACRV had 1.4M shares sold short — 4.9% of its float, with 4.3 days to cover at average volume. FINRA publishes this data roughly two weeks after each twice-monthly settlement, so it is inherently delayed. A short-interest figure describes an aggregate position; it does not predict what the stock will do.
Are insiders buying ACRV?
In the last 12 months of SEC Form 4 filings, ACRV recorded 0 open-market insider purchases and 6 open-market sales (codes P and S; grants and option exercises excluded). These are attributed public records — information, not instruction.
Is this page telling me to buy or sell ACRV?
No. Everything on this page is descriptive, structural market context from public data, shown with its as-of dates. TradeAI News does not issue directional recommendations, price predictions, or buy/sell advice — for any ticker.